RxDoctor Payments Data

Monica Gomez, NP

Family · Michigan City, INNPI 1447822697

Payments from drug & device makers

$479in general payments, 2019–2025

Across 29 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$275
  • AstraZeneca$35
  • Exact Sciences$29
  • Corium, LLC$25
  • Teva Pharmaceuticals USA, Inc.$23
  • Lilly USA, LLC$22
  • plus $70 from 4 others

What the payments were for

  • Food & beverage$479100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie16$275
AstraZeneca2$35
Exact Sciences2$29
Corium, LLC3$25
Teva Pharmaceuticals USA, Inc.1$23
Lilly USA, LLC1$22
GSK1$21
Gilead1$17
Cipher Pharmaceuticals US LLC1$17
Otsuka America Pharmaceutical, Inc.1$15

How this compares

$479 in reported general payments places this provider in the 50th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$301
Medicare patients
14
Services billed
28

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$69,416
JardianceEmpagliflozin26$22,321
JanuviaSitagliptin Phosphate15$17,075
VraylarCariprazine Hcl12$16,120
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$12,368
Humulin R U-500 KwikpenInsulin Regular, Human11$12,317
TradjentaLinagliptin13$6,260
Levemir FlexpenInsulin Detemir17$3,588
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$3,300
Atorvastatin Calcium150$1,169
Albuterol Sulfate HfaAlbuterol Sulfate53$858
Wixela InhubFluticasone Propion/Salmeterol13$683
ValacyclovirValacyclovir Hcl11$648
Gabapentin79$598
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$275$16,12012 claims
GSKAnoro Ellipta$21$12,36826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,392 family providers in Indiana.

Other family in Michigan City

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →